Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Ipsen S.A. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
IPSEY
Over the counter
2834
www.ipsen.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Ipsen S.A.
Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
- Feb 6th, 2025 5:00 pm
Ipsen - Half year statement - 2024 12 31
- Jan 7th, 2025 5:00 pm
Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
- Jan 7th, 2025 5:00 pm
Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
- Dec 9th, 2024 5:00 pm
Ipsen and Biomunex enter agreement for cancer therapy
- Dec 4th, 2024 10:40 am
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
- Dec 3rd, 2024 6:00 am
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
- Nov 18th, 2024 6:00 am
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
- Nov 15th, 2024 4:00 pm
Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
- Nov 7th, 2024 5:00 pm
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
- Oct 23rd, 2024 5:00 am
Ipsen receives its second Shingo Prize for operational excellence
- Oct 14th, 2024 4:00 pm
Ipsen SA (IPSEF) (H1 2024) Earnings Call Highlights: Strong Sales Growth Amidst Challenges
- Oct 9th, 2024 7:13 pm
Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
- Oct 9th, 2024 4:00 pm
Ipsen’s Elafibranor gains MHRA approval for PBC treatment
- Oct 9th, 2024 9:15 am
Ipsen’s Iqirvo wins European approval for primary biliary cholangitis
- Sep 23rd, 2024 2:53 pm
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
- Sep 23rd, 2024 11:13 am
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
- Sep 20th, 2024 12:57 pm
Ipsen shelves Cabometyx combo in prostate cancer after Phase III miss
- Sep 16th, 2024 1:13 pm
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
- Sep 16th, 2024 12:45 pm
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
- Sep 15th, 2024 12:45 pm
Scroll